American Society of Hematology: Gene Therapy Leads to Improved Quality of Life in Patients With Sickle Cell Disease and Beta Thalassemia
August 28, 2025
August 28, 2025
WASHINGTON, Aug. 28 (TNSjou) -- The American Society of Hematology issued the following news release on Aug. 27, 2025:
* * *
Gene Therapy Leads to Improved Quality of Life in Patients with Sickle Cell Disease and Beta Thalassemia
Substantial improvements seen across ages in overall health and wellbeing
*
Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with s . . .
* * *
Gene Therapy Leads to Improved Quality of Life in Patients with Sickle Cell Disease and Beta Thalassemia
Substantial improvements seen across ages in overall health and wellbeing
*
Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with s . . .